An Off-the-Shelf Vaccine Could Give Doctors a New Tool Against Leukemia
Sellas Life Sciences and Memorial Sloan Kettering Cancer Center reported that the experimental leukemia vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% in a Phase 3 trial. The vaccine, tested on 126 patients with acute myeloid leukemia (AML) in remission, showed a median overall survival of 24 months compared to 14.7 months with other treatments. Sellas plans to discuss regulatory approval with the FDA and submit a Biologics License Application in 2027.
How this was made

The 30-second read
Why it matters
The article reports a Phase 3 REGAL trial outcome with an overall survival advantage and supportive safety, plus stated intent to engage the FDA and submit a Biologics License Application in 1H 2027.
Market read
Traders can reassess approval probability and timeline for an AML maintenance immunotherapy program based on the reported Phase 3 survival benefit and next regulatory steps.
What to watch
Key missing items for trading include hazard ratios, confidence intervals, interim vs final analysis framing, comparator specifics, and whether FDA will require additional endpoints or confirmatory data.
Background
GPS (galinpepimut-S) is an off-the-shelf peptide vaccine targeting WT1 for AML patients in second or later complete remission who cannot undergo donor stem cell transplant, positioned as maintenance immunotherapy.
Ticker impact
Sellas Life Sciences is the developer of galinpepimut-S (GPS), reporting Phase 3 REGAL results with a 41% death-risk reduction and plans for FDA filing.
Likely upward bias as traders price in higher odds of FDA acceptance and a clearer path to commercialization.
The article cites statistically significant overall survival benefit, supportive safety, and an FDA discussion plus BLA preparation timeline into 1H 2027, which are decision-relevant catalysts for a biotech.
Market effects
Adds incremental evidence for off-the-shelf peptide immunotherapy in AML maintenance, potentially improving sentiment toward cancer vaccine platforms.
Primarily US biotech sentiment, with spillover to oncology vaccine peers and clinical-stage immunotherapy names.
Supports the broader global oncology vaccine narrative, though the immediate tradable impact is concentrated in US-listed biotech.
Counterpoint
Phase 3 success may not translate into approval or durable benefit across broader AML populations, and the article lacks full subgroup and statistical detail.
Key entities
- companySellas Life Sciences
Developer of the GPS (galinpepimut-S) off-the-shelf AML vaccine and presenter of Phase 3 REGAL results.
- institutionMemorial Sloan Kettering Cancer Center
Co-developer/clinical research partner associated with the vaccine program.
- regulatorFDA
Regulatory authority Sellas plans to discuss the regulatory path with before BLA submission.



